Alamar Biosciences, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Alamar reported Q2 2026 revenue of $29.4M (up 82% YoY), driven by consumable revenue growth of 147% to $15.5M. The company raised full-year 2026 revenue guidance to $116–120M (59% growth midpoint), launched eMTBR-tau immunoassay and Immune 340 Panel, and expanded partnership with Alzheimer's Disease Data Initiative. Cash position: $256.3M as of June 30, 2026.
Why this rating
Strong revenue acceleration and consumable mix shift improve unit economics. Guidance raise and cash cushion support growth trajectory. However, operating losses ($13.5M Q2, $25.9M H1) and 89% expense growth limit near-term profitability despite revenue scale.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.